Shots:
- Saluda Medical has reported the European CE Mark approval of its EVA Sensing Technology to manage pain with spinal cord stimulation, with recognition of this approval in Australia
- The company is planning a limited commercial launch in EU & Australia for Q1’26, followed by a full commercial rollout in both regions later in the year
- EVA objectively scans & analyzes the spinal cord to deliver personalized therapy with precision & is built on the Evoke Systems, which optimize outcomes by reading & responding based on each patient’s ECAPs to maintain therapy
Ref: PRnewswire | Image: Saluda Medical |Press Release
Related News: Saluda Medical Reports Full Launch of EVA Sensing Technology for Spinal Cord Stimulation in the US
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
